XML 72 R61.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]        
Net sales $ 651.6 $ 638.5 $ 1,237.0 $ 1,249.3
Gross profit 345.3 355.1 651.3 681.1
Selling, general and administrative expense (207.7) (194.7) (416.5) (409.6)
Research and Development Expense (60.5) (58.9) (134.0) (125.3)
Interest expense (12.6) (12.3) (24.6) (24.5)
Foreign Currency Transaction Gain (Loss), before Tax (1.1) 1.7 1.6 3.7
Marketable Securities, Unrealized Gain (Loss) 334.4 (2,895.4) 366.2 (2,473.2)
Other Nonoperating Income (Expense) 16.2 18.2 53.4 52.6
Operating Segments        
Segment Reporting Information [Line Items]        
Gross profit 345.3 355.1    
Income before income taxes     651.3 681.1
Selling, general and administrative expense (207.7) (194.7) (416.5) (409.6)
Research and Development Expense (60.5) (58.9) (134.0) (125.3)
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment        
Segment Reporting Information [Line Items]        
Foreign Currency Transaction Gain (Loss), before Tax (1.1) 1.7 1.6 3.7
Marketable Securities, Unrealized Gain (Loss) 334.4 (2,895.4) 366.2 (2,473.2)
Other Nonoperating Income (Expense) 16.2 18.2 53.4 52.6
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment | Interest Expense        
Segment Reporting Information [Line Items]        
Interest expense (12.6) (12.3) 24.6 24.5
Life Science        
Segment Reporting Information [Line Items]        
Net sales 262.8 250.5 491.4 492.2
Gross profit 148.3 144.6 276.7 276.3
Clinical Diagnostics        
Segment Reporting Information [Line Items]        
Net sales 388.8 388.0 745.6 756.6
Gross profit 197.0 210.5 374.6 404.9
Other Operating Segment        
Segment Reporting Information [Line Items]        
Net sales 0.0 0.0 0.0 0.5
Gross profit $ 0.0 $ 0.0 $ 0.0 $ (0.1)